FDA Announces Public Meeting on Patient-Focused Drug Development for Neurologic Manifestations of Inborn Errors of Metabolism

Summary

The FDA is hosting a public meeting to gather patient perspectives on the impact of neurologic manifestations of inborn errors of metabolism on daily life and treatment approaches, as part of its performance commitments under the Prescription Drug User Fee Act (PDUFA V).